alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
```

[Congressional Bills 104th Congress]
[From the U.S. Government Publishing Office]
[S. 1636 Enrolled Bill (ENR)]

        S.1636

                       One Hundred Fourth Congress

                                 of the

                        United States of America

                          AT THE SECOND SESSION

         Begun and held at the City of Washington on Wednesday,
   the third day of January, one thousand nine hundred and ninety-six

                                 An Act

 
  To designate the United States Courthouse under construction at 1030 
Southwest 3rd Avenue, Portland, Oregon, as the ``Mark O. Hatfield United 
              States Courthouse'', and for other purposes.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. DESIGNATION OF MARK O. HATFIELD UNITED STATES COURTHOUSE.

    The United States Courthouse under construction at 1030 Southwest 
3rd Avenue in Portland, Oregon, shall be known and designated as the 
``Mark O. Hatfield United States Courthouse''.

SEC. 2. REFERENCES.

    Any reference in a law, map, regulation, document, paper, or other 
record of the United States to the courthouse referred to in section 1 
shall be deemed to be a reference to the ``Mark O. Hatfield United 
States Courthouse''.

SEC. 3. EXTENSION OF FDR MEMORIAL MEMBER TERMS.

    The first section of the Act entitled ``An Act to establish a 
commission to formulate plans for a memorial to Franklin Delano 
Roosevelt'', approved August 11, 1955 (69 Stat. 694) is amended by 
adding at the end thereof the following: ``A Commissioner who ceases to 
be a Member of the Senate or the House of Representatives may, with the 
approval of the appointing authority, continue to serve as a 
Commissioner for a period of up to one year after he or she ceases to 
be a Member of the Senate or the House of Representatives.''.

SEC. 4. EFFECTIVE DATE.

    This Act shall take effect on January 3, 1997.

                               Speaker of the House of Representatives.

                            Vice President of the United States and    
                                               President of the Senate.
```
EXHIBIT 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906
OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report on Form 10-K for the year ended December 31, 2008 of
D&E Communications, Inc. (the Company) as filed with the Securities and Exchange Commission on the date hereof (the Report), I, Thomas E. Morell, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C.
Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

1. The Report fully complies with the
requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934; and

2. The information contained in the
Report fairly presents, in all material respects, the financial condition and results of operations of the Company.



/s/    THOMAS E.
MORELLName:

Thomas E. MorellTitle:

Chief Financial OfficerDate:

March 12, 2009
<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
This schedule contains summary financial information extracted from the Balance
Sheet of Adams Outdoor Advertising Limited Partnership as of December 31, 1999
and the related Statements of Operations and Cash Flows and is qualified in its
entirety by reference to such financial statements.
</LEGEND>
<CIK> 0001011977
<NAME> ADAMS OUTDOOR ADVERTISING, INC.
<MULTIPLIER> 1,000

<S>                             <C>
<PERIOD-TYPE>                   12-MOS
<FISCAL-YEAR-END>                          DEC-31-1999
<PERIOD-START>                             JAN-01-1999
<PERIOD-END>                               DEC-31-1999
<CASH>                                           1,616
<SECURITIES>                                     3,166
<RECEIVABLES>                                   10,230
<ALLOWANCES>                                   (1,167)
<INVENTORY>                                         93
<CURRENT-ASSETS>                                17,609
<PP&E>                                         125,535
<DEPRECIATION>                                (69,009)
<TOTAL-ASSETS>                                  82,106
<CURRENT-LIABILITIES>                            8,198
<BONDS>                                        118,947
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                             0
<OTHER-SE>                                    (65,167)
<TOTAL-LIABILITY-AND-EQUITY>                    82,106
<SALES>                                         68,040
<TOTAL-REVENUES>                                68,040
<CGS>                                                0
<TOTAL-COSTS>                                   39,647
<OTHER-EXPENSES>                                 6,930
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                              13,363
<INCOME-PRETAX>                                  5,781
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                              5,975
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                  (194)
<CHANGES>                                            0
<NET-INCOME>                                     5,781
<EPS-BASIC>                                          0
<EPS-DILUTED>                                        0


</TABLE>
EXHIBIT 32.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER  CALLISTO PHARMACEUTICALS, INC.  FORM 10-Q FOR THE QUARTER ENDED MARCH 31, 2011  PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED
PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I am the Chief Executive Officer of Callisto Pharmaceuticals, Inc., a Delaware corporation (the "Company"). I am delivering this
certificate in connection with the Form 10-Q of the Company for the quarter ended March 31, 2011 and filed with the Securities and Exchange Commission
("Form 10-Q").

Pursuant
to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, I hereby certify that, to the best of my knowledge, the
Form 10-Q fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934 and that the information contained in the
Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: May 16, 2011

/s/ GARY S. JACOB Gary S. Jacob Chief Executive Officer


---



QuickLinks
Exhibit 32.1



CERTIFICATION



Pursuant to 18 U.S.C. ss. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of Mission Broadcasting,
Inc. (the Company), hereby certifies that, to his knowledge, the Companys Quarterly Report on Form 10-Q for the three months ended September 30, 2004 (the Report) fully complies with the requirements of Section 13(a) or
15(d), as applicable, of the Securities Exchange Act of 1934 and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.



Dated: November 15, 2004



/s/ DAVID S. SMITHDavid S. SmithPresident and Treasurer(Principal Executive Officer andPrincipal Financial and Accounting Officer)




The foregoing
certification is being furnished solely pursuant to 18 U.S.C. ss. 1350 and is not being filed as part of the Report or as a separate disclosure document.
##### 



EXHIBIT 31.1
 CERTIFICATIONS
 Certification pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934,
as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
             By:
    /s/    H.K. DesaiH.K. DesaiChief Executive Officer
EXHIBIT 31.1

CERTIFICATIONS

I,
Gary S. Jacob, certify that:

1)    I
have reviewed this quarterly report on Form 10-Q of Callisto Pharmaceuticals, Inc.

2)    Based
on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements
made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report;

3)    Based
on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial
condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this quarterly report;

4)    The
registrant's other certifying officer and I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act
Rules 13a-14 and 15d-14) for the registrant and we have:



5)    The
registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's
auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions);



Date: August 16, 2010

/s/ GARY S. JACOB Gary S. Jacob Chief Executive Officer


---
<TABLE> <S> <C>

<ARTICLE>  5
<LEGEND>
This schedule contains summary financial information extracted from the
balance sheets and statements of operations found on pages F-2 and F-3 of
the Company's Form 10-KSB for the fiscal year ended December 31, 1999 and is
qualified in its entirety by reference to such financial statements.
</LEGEND>
<PERIOD-TYPE>                          YEAR
<FISCAL-YEAR-END>               DEC-31-1999
<PERIOD-END>                    DEC-31-1999
<CASH>                              215,026
<SECURITIES>                              0
<RECEIVABLES>                         8,857
<ALLOWANCES>                          2,786
<INVENTORY>                         129,398
<CURRENT-ASSETS>                    373,794
<PP&E>                              615,883
<DEPRECIATION>                      197,336
<TOTAL-ASSETS>                    1,089,656
<CURRENT-LIABILITIES>               387,918
<BONDS>                                   0
<PREFERRED-MANDATORY>                     0
<PREFERRED>                               0
<COMMON>                              1,154
<OTHER-SE>                          389,948
<TOTAL-LIABILITY-AND-EQUITY>      1,089,656
<SALES>                              62,851
<TOTAL-REVENUES>                    962,836
<CGS>                               110,550
<TOTAL-COSTS>                       288,262
<OTHER-EXPENSES>                  1,099,671
<LOSS-PROVISION>                          0
<INTEREST-EXPENSE>                   35,213
<INCOME-PRETAX>                    (386,547)
<INCOME-TAX>                              0
<INCOME-CONTINUING>                (386,547)
<DISCONTINUED>                            0
<EXTRAORDINARY>                           0
<CHANGES>                                 0
<NET-INCOME>                       (386,547)
<EPS-BASIC>                          (.03)
<EPS-DILUTED>                          (.03)


</TABLE>
EXHIBIT 10.37


                           IVP TECHNOLOGY CORPORATION




                                          July 31, 2001


Buford Industries Inc.,
Drake Chambers,
Road Town, Tortola,
British Virgin Islands
3321

                        DELIVERED BY FAX AND CANADA POST

Dear Sirs:

      RE:   IVP TECHNOLOGY CORPORATION ("IVP") INTERNATIONAL TECHNOLOGY
            MARKETING INC. ("INTERNATIONAL") SHARE EXCHANGE

      Further to our telephone  conversation  of today's date, I hereby  confirm
our  corporate  understanding  and  agreement  to  pay  Buford  Industries  Inc.
("Buford") the sum of one hundred thousand American dollars (USD 100,000) in the
event that the  above-referenced  share exchange is completed.  The fee is to be
paid to Buford in full and complete  satisfaction for services  rendered to IVP,
specifically the introduction of International's  management team to IVP for the
purpose  of  effecting  the  share  exchange.  The fee  will be paid in two cash
installments of USD 50,000. The first installment is to be payable at closing of
the share exchange and the second installment is to be paid one year thereafter.

      This  letter  is a  confirmation  only.  IVP  will  provide  such  further
assurance as may be  appropriate  or  reasonably  required by the  management of
Buford.

                                          Yours truly,

                                          IVP Technology Corporation

                                    Per:  /S/ JOHN TRAINOR
                                          ------------------------
                                          John Trainor, Secretary


JT/rmr





         54 VILLAGE CENTRE PLACE, SUITE 300, MISSISSAUGA, ONTARIO L4Z1V9
                            TELEPHONE (905) 306-9343
<TABLE> <S> <C>

<ARTICLE> 5

<S>                             <C>
<PERIOD-TYPE>                   12-MOS
<FISCAL-YEAR-END>                          DEC-31-1996
<PERIOD-END>                               DEC-31-1996
<CASH>                                               0
<SECURITIES>                                         0
<RECEIVABLES>                                        0
<ALLOWANCES>                                         0
<INVENTORY>                                          0
<CURRENT-ASSETS>                                     0
<PP&E>                                               0
<DEPRECIATION>                                       0
<TOTAL-ASSETS>                                       0
<CURRENT-LIABILITIES>                                0
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                       1000
<COMMON>                                         74150
<OTHER-SE>                                           0
<TOTAL-LIABILITY-AND-EQUITY>                         0
<SALES>                                              0
<TOTAL-REVENUES>                                     0
<CGS>                                                0
<TOTAL-COSTS>                                        0
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                   0
<INCOME-PRETAX>                                      0
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                                  0
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                         0
<EPS-BASIC>                                          0
<EPS-DILUTED>                                        0


</TABLE>
IN THE SUPREME COURT OF PENNSYLVANIA

MIDDLE DISTRICT

COMMONWEALTH OF PENNSYLVANIA,

Respondent

v.

JUAN CARLOS ALVAREZ,

Petitioner :

:

:

:

:

:

:

:

:

:

: No. 569 MAL 2017

Petition for Allowance of Appeal from

the Order of the Superior Court

ORDER

PER CURIAM

AND NOW , this 26th day of December, 2017

, the Petition for Allowance of

Appeal is DENIED

.
##### Table of Contents



UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
 WASHINGTON, D.C. 20549
 
 FORM 8-K
 
 CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
 Date of Report (date of earliest event reported): April 8, 2009
 
 MINDSPEED TECHNOLOGIES, INC.
  
 Delaware
    
    000-50499
    
    01-0616769(State or Other Jurisdiction of 
Incorporation or Organization)
    
    (Commission File Number)
    
    (I.R.S. Employer
Identification No.)
 4000 MacArthur Boulevard, East Tower
Newport Beach, California 92660-3095
 (949) 579-3000
 
  o
 o
 o
 o




---



TABLE OF CONTENTS  Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersSIGNATURE    Table of Contents  
 Item 5.02
    
    Departure of Directors or Certain Officers; Election of Directors; Appointment of
Certain Officers; Compensatory Arrangements of Certain Officers




---



##### Table of Contents



SIGNATURE
  MINDSPEED TECHNOLOGIES, INC.Date:  April 13, 2009
    By:
    /s/ Bret W. JohnsenBret W. JohnsenSenior Vice President, Chief Financial
Officer and Treasurer
Exhibit 4.1


D & E Communications, Inc.
Form of Stock Certificate


   NUMBER                                                      SHARES


COMMON STOCK                                                       COMMON STOCK
                                                               CUSIP 232860 10 6
                           D & E Communications, Inc.
                              Ephrata, Pennsylvania
         Incorporated under the laws of the Commonwealth of Pennsylvania

This Certifies that



is the owner of

             Full paid and non-assessable shares of the par value of
                   sixteen cents each of the common stock of
                           D & E Communications, Inc.
transferable on the books of the Company in person or by duly authorized
attorney upon surrender of this Certificate, properly endorsed.
   WITNESS of the Seal of said Company and the signatures of its duly
authorized officers.

Dated:

                  SECRETARY                                        PRESIDENT
Phantom Vision 2+ Check List 

Legal: 

❑ Verify appropriate NOTAMs placed 

❑ Location/people authorizations/releases 

❑ TFRs/Airspace/Airport proximity 

❑ AII operating documents on hand 

❑ Review PIC requirements, current condition 

❑ (1 AM SAFE), currency requirements 

Environment• 

❑ Weather (Day, VFR, 3+ SM vis, Clouds 500 v 2000 h, Wind <= 10 mph 

❑ Warning signs posted 

❑ Hazards, obstructions, pedestrian or vehicular traffic in flight path 

❑ Non essential personnel cleared/behind barriers 

Vehicle: 

❑ Review maintenance records 

❑ Inspect for damage 

❑ Props correctly installed 

❑ Memory card installed 

❑ Remote Controller, smart battery, range extender and screen fully charged. 

❑ Propellers mounted correctly. 

❑ Gimbal clamp, lens cap removed. 

❑ Damping absorbers are in good condition, not broken or worn. 

❑ Anti-drop kits have been mounted correctly. 

❑ Micro-SD card has been inserted if necessary. 

❑ Gimbal is functioning as normal. 

❑ Motors can start and are functioning as normal. 

Pre flight: 

❑ Note flight path, review with 2nd VO. Note max height with trees, structures. 

❑ Review emergency procedures/automated landing system 

❑ Turn on radio to monitor local flight traffic 

❑ DJI VISION App can connect to the camera. 

❑ Note starting elevation (ASL=O AGL) 

Flight: 

❑ < 30 Knots, 300 ft AGL 

❑ Power on remote, vehicle, wifi extender, screen device 

❑ Calibrate compass if needed (toggle S1 switch 6x, rotate UA 3600 H& V) 

❑ Check rear LED flight indicators 

❑ Check 6+ satellites (DJI Vision App) 

❑ Scan flight environment 

❑ Start props, hold at 5 feet, check controls. 

❑ Fly plan, line of sight 

❑ Note any incident, accident (report) 

Landing: 

❑ Land with >=30% battery power 

❑ Power off UA, remote, wifi extender. Disconnect screen device 

❑ Replace gimbal clamp, lens cap 

❑ Post flight inspection, note damage, maintenance issues.
EXHIBIT 21SUBSIDIARIES OF THE REGISTRANT          Valeant Pharmaceuticals International is incorporated in the State of Delaware. Thefollowing table shows the Company’s subsidiaries as of December 31, 2007, the percentage of theirvoting securities (including directors’ qualifying shares) then owned, directly or indirectly bythe Company, and the jurisdiction under which each subsidiary is incorporated. These subsidiariesare included in the Company’s consolidated financial statements.                  PERCENTAGE    OF VOTING  JURISDICTION SECURITIES OWNED  OF BY COMPANY  INCORPORATION OR SUBSIDIARYValeant Argentina S.A. Argentina  100 Laboratorios Valeant Argentina S.A. Argentina  100 Valeant Pharmaceuticals Australasia Pty. Ltd. Australia  100 Valeant Farmaceutica do Brasil Ltda. Brazil  100 Valeant Canada Ltd. Canada  100 Valeant Canada Holdings Ltd. Canada  100 Valeant Pharma Hungary Commercial LLC Hungary  100 Valeant Farmaceutica, S.A. de C.V. Mexico  100 Laboratorios Grossman, S.A. Mexico  100 Logistica Valeant S.A. de C.V. Mexico  100 Valeant Biomedicals Dutch Holdings B.V. Netherlands  100 Valeant Dutch Holdings B.V. Netherlands  100 ICN Polfa Rzeszow S.A. Poland  99 Valeant Global Pte. Ltd. Singapore  100 Valeant Pharmaceuticals Singapore Pte. Ltd. Singapore  100 Valeant Singapore Pte. Ltd. Singapore  100 Valeant Pharmaceuticals Switzerland GmbH Switzerland  100 Valeant Biomedicals, Inc. Delaware (USA)  100 Valeant Pharmaceuticals North America Delaware (USA)  100           * In accordance with the instructions of Item 601 of Regulation S-K, certain subsidiaries are omitted from the foregoing table.
#### CATHOLIC SOCIAL SERVICES, INC. (CENTRO DE GUADALUPE IMMIGRATION CENTER); California Coalition of Welfare Center for Immigrants Rights, Inc.; Mercedes Aguilar De Lopez; Maria Teresa Reyes; and Sara Orantes De Palacios, Plaintiffs-Appellants and Cross-Appellees, v. Janet RENO,* Attorney General of the United States of America, Defendant-Appellee and Cross-Appellant.

Nos. 88-15046, 88-15127 and 88-15128.

United States Court of Appeals, Ninth Circuit.

July 7, 1993.

*222Before GOODWIN, SNEED, and HUG, Circuit Judges.

*

 Janet Reno is substituted for her predecessor, Richard Thornburgh, as Attorney General of the United States of America.

ORDER

Pursuant to the order of remand of the United States Supreme Court in *Reno, Attorney General, et al. v. Catholic Social Services, Inc., et al.,*— U.S.-, 113 S.Ct. 2485, 125 L.Ed.2d 38 (1993), this case is remanded to the district court for further proceedings consistent with that opinion.
August 23, 2016

JUDGMENT

The Fourteenth Court of Appeals

CARLOS GALLEGOS-PIEDRA, Appellant

NO. 14-14-01026-CR V.

THE STATE OF TEXAS, Appellee

________________________________

This cause was heard on the transcript of the record of the court below. 

Having considered the record, this Court holds that there was no error in the 

judgment. The Court orders the judgment AFFIRMED.

We further order appellant pay all costs expended in the appeal.

We further order this decision certified below for observance.
##### 



Exhibit 3.3
 STATE OF DELAWARE
CERTIFICATE OF CORRECTION OF THE
CERTIFICATE OF AMENDMENT
OF
VALEANT PHARMACEUTICALS INTERNATIONAL
 Valeant Pharmaceuticals International Corporation Does Hereby
Certify
 1.
    
    The name of the Corporation is Valeant Pharmaceuticals International.2.
    
    That a Certificate of Amendment to the Restated Certificate of Incorporation of ICN
Pharmaceuticals, Inc was filed with the Secretary of State of the State of Delaware on July
10, 1998 (the Amendment) and that said Amendment requires correction as permitted by
Section 103 of the General Corporation Law of the State of Delaware.3.
    
    The inaccuracy or defect of said Amendment is:The first sentence of Article First of the Amendment contains a typographical error. The
Amendment was intended to amend the first paragraph only of Article Fourth of the Restated
Certificate of Incorporation of the Corporation.4.
    
    Article First of the Amendment is corrected to read as follows:
 FIRST
 FOURTH:The total number of shares for all classes of capital stock which
the Corporation shall have the authority to issue is Two Hundred and Ten
Million (210,000,000) shares divided into two classes of which Ten Million
(10,000,000) shares, par value $.01 per share, shall be designated
Preferred Stock and Two Hundred Million (200,000,000) shares, par value
$.01 per share, shall be designated Common Stock.
 In Witness Whereof
 Valeant Pharmaceuticals InternationalBy:
    /s/ Bary G. BaileyBary G. BaileyExecutive Vice President and Chief Financial Officer